Details
Stereochemistry | RACEMIC |
Molecular Formula | 2C17H20N2S.C15H12O6 |
Molecular Weight | 857.09 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C.CC(CN4C5=C(SC6=C4C=CC=C6)C=CC=C5)N(C)C.OC(=O)C7=CC(CC8=CC(C(O)=O)=C(O)C=C8)=CC=C7O
InChI
InChIKey=QOLHOCYZKJILAV-UHFFFAOYSA-N
InChI=1S/2C17H20N2S.C15H12O6/c2*1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19;16-12-3-1-8(6-10(12)14(18)19)5-9-2-4-13(17)11(7-9)15(20)21/h2*4-11,13H,12H2,1-3H3;1-4,6-7,16-17H,5H2,(H,18,19)(H,20,21)
Molecular Formula | C17H20N2S |
Molecular Weight | 284.419 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C15H12O6 |
Molecular Weight | 288.2522 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Promethazine is a phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12657913 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Preventing | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.28 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21.84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
48.26 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
19.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.04 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11511 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14466 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
146.62 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
180.14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
627.13 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
146 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
361 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
256 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
17.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Disc. AE: Sinus tachycardia, Consciousness decreased... AEs leading to discontinuation/dose reduction: Sinus tachycardia Sources: Page: p.242Consciousness decreased Agitation Confusion Disorientation Visual hallucinations Delirium |
160 mg single, intramuscular Highest studied dose Dose: 160 mg Route: intramuscular Route: single Dose: 160 mg Sources: Page: p.199 |
healthy, 21.4±1.7 n = 6 Health Status: healthy Age Group: 21.4±1.7 Sex: M+F Population Size: 6 Sources: Page: p.199 |
|
120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: Page: p.199 |
healthy, 22.7±2.31 n = 10 Health Status: healthy Age Group: 22.7±2.31 Sex: M+F Population Size: 10 Sources: Page: p.199 |
|
80 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 80 mg, 1 times / day Route: intramuscular Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p.199 |
healthy, 24.2±1.17 n = 10 Health Status: healthy Age Group: 24.2±1.17 Sex: M+F Population Size: 10 Sources: Page: p.199 |
|
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Disc. AE: Respiratory depression, Irritation skin... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 5) Sources: Page: p.1Irritation skin (severe) Pain Thrombophlebitis |
50 mg single, oral (max) Recommended Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: Page: p.2, 3 |
unhealthy Health Status: unhealthy Condition: Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation Sources: Page: p.2, 3 |
Disc. AE: Respiratory depression... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 5) Sources: Page: p.2, 3 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Confusion | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Consciousness decreased | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Delirium | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Disorientation | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Sinus tachycardia | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Visual hallucinations | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Pain | Disc. AE | 50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Thrombophlebitis | Disc. AE | 50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Respiratory depression | grade 5 Disc. AE |
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Irritation skin | severe Disc. AE |
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Respiratory depression | grade 5 Disc. AE |
50 mg single, oral (max) Recommended Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: Page: p.2, 3 |
unhealthy Health Status: unhealthy Condition: Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation Sources: Page: p.2, 3 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 32 uM] | ||||
yes [Inhibition 88 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Antihypertensive therapy in critical occupations: studies with an angiotensin II antagonist. | 2001 Dec |
|
[Evaluation and treatment of hyperemesis gravidarum]. | 2001 Dec |
|
[Work time distribution in night shift: are clinics facing a adjustment boom?]. | 2001 Jul |
|
Adverse reactions related to phenergan. | 2001 May-Jun |
|
The use of on-line and off-line chromatographic extraction techniques coupled with mass spectrometry for support of in vivo and in vitro assays in drug discovery. | 2001 Nov |
|
Standard treatment: the role of antihistamines. | 2001 Nov |
|
Codeine ingestion and apparent life-threatening event in a neonate. | 2001 Oct |
|
[Suicidal attempts with old (currently unused) drug]. | 2002 |
|
Antiallergic anti-inflammatory effects of H1-antihistamines in humans. | 2002 |
|
Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. | 2002 |
|
Investigation of the effect of tablet surface area/volume on drug release from hydroxypropylmethylcellulose controlled-release matrix tablets. | 2002 Apr |
|
Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction. | 2002 Apr |
|
Toxicity of ethacrynic acid in isolated rat hepatocytes. | 2002 Apr |
|
Study of the stability of promethazine enantiomers by liquid chromatography using a vancomycin-bonded chiral stationary phase. | 2002 Apr 25 |
|
A systematic approach to the management of postoperative nausea and vomiting. | 2002 Dec |
|
Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. | 2002 Feb |
|
Low-molecular-weight chiral cation exchangers: novel chiral stationary phases and their application for enantioseparation of chiral bases by nonaqueous capillary electrochromatography. | 2002 Feb |
|
An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. | 2002 Jan |
|
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. | 2002 Jan 7 |
|
Investigation of interaction of promethazine with cyclodextrins. | 2002 Jan-Feb |
|
Bradykinin is involved in hyperalgesia induced by Bothrops jararaca venom. | 2002 Jul |
|
Recovery, enrichment and selectivity in liquid-phase microextraction comparison with conventional liquid-liquid extraction. | 2002 Jul 19 |
|
Project USAP 2000--use of sedative agents by pediatric dentists: a 15-year follow-up survey. | 2002 Jul-Aug |
|
Indirect spectrophotometric determination of propranolol hydrochloride and piroxicam in pure and pharmaceutical formulations. | 2002 Jun |
|
Central effects of cinnarizine: restricted use in aircrew. | 2002 Jun |
|
Next generation antihistamines: therapeutic rationale, accomplishments and advances. | 2002 Jun |
|
Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. | 2002 Jun 19 |
|
[Validation of the HPLC method in the determination of dioxopromethazine and phenylephrine in eye drops]. | 2002 Mar |
|
Cesarean delivery: a randomized trial of epidural analgesia versus intravenous meperidine analgesia during labor in nulliparous women. | 2002 Mar |
|
Treatment patterns of isolated benign headache in US emergency departments. | 2002 Mar |
|
Nanoparticles in plant extracts: influence of drugs on the formation of nanoparticles and precipitates in black tea infusions. | 2002 Mar |
|
Interaction of protonated anticancer thiazines with water-insoluble phospholipids and antineoplastic agents. | 2002 Mar-Apr |
|
Liquid-phase microextraction of protein-bound drugs under non-equilibrium conditions. | 2002 May |
|
Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial. | 2002 May |
|
Simultaneous determination of promethazine, chlorpromazine, and perphenazine by multivariate calibration methods and derivative spectrophotometry. | 2002 May-Jun |
|
Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians. | 2002 Nov-Dec |
|
TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243]. | 2002 Oct 16 |
|
[Landau-Kleffner and autistic regression: the importance of differential diagnosis]. | 2002 Sep |
|
A case of homicide by lethal injection with lidocaine. | 2002 Sep |
|
A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. | 2002 Winter |
|
The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. | 2003 Apr |
|
Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. | 2003 Apr |
|
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. | 2003 Apr |
|
Inactivation of cholinesterase induced by chlorpromazine cation radicals. | 2003 Feb |
|
Effect of phenothiazines on protein kinase C- and calcium-dependent activation of peritoneal macrophages. | 2003 Feb |
|
Reye's syndrome: down but not out. | 2003 Jan |
|
In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. | 2003 Jan |
|
Phenothiazine radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase: enzyme protection by radical scavengers. | 2003 Mar |
|
Clinical practice. Vestibular neuritis. | 2003 Mar 13 |
|
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants. | 2003 May |
Sample Use Guides
Allergy: the average oral dose is 25 mg taken before retiring; however, 12.5 mg may be taken before meals and on retiring, if necessary. Single 25 mg doses at bedtime or 6.25 to 12.5 mg taken three times daily will usually suffice. After initiation of treatment in children or adults, dosage should be adjusted to the smallest amount adequate to relieve symptoms. The administration of promethazine HCI in 25 mg doses will control minor transfusion reactions of an allergic nature.
Motion Sickness: the average adult dose is 25 mg taken twice daily. The initial dose should be taken one-half to one hour before anticipated travel and be repeated 8 to 12 hours later, if necessary. On succeeding days of travel, it is recommended that 25 mg be taken on arising and again before the evening meal. For children, 12.5 to 25 mg, twice daily, may be administered.
Nausea and Vomiting: antiemetics should not be used in vomiting of unknown etiology in children and adolescents. The average effective dose of Promethazine HCL Oral Solution for the active therapy of nausea and vomiting in children or adults is 25 mg. When oral medication cannot be tolerated, the dose should be given parenterally or by rectal suppository. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. For nausea and vomiting in children, the usual dose is 0.5 mg per pound of body weight, and the dose should be adjusted to the age and weight of the patient and the severity of the condition being treated.
For prophylaxis of nausea and vomiting, as during surgery and the postoperative period, the average dose is 25 mg repeated at 4 to 6 hour intervals, as necessary.
Sedation: this product relieves apprehension and induces a quiet sleep from which the patient can be easily aroused. Administration of 12.5 to 25 mg Promethazine HCl Oral Solution by the oral route will provide sedation in children. Adults usually require 25 to 50 mg for nighttime, presurgical, or obstetrical sedation.
Pre- and Postoperative Use: promethazine HCl Oral Solution in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep.
For preoperative medication, children require doses of 0.5 mg per pound of body weight in combination with an appropriately reduced dose of narcotic or barbiturate and the appropriate dose of an atropine-like drug.
Usual adult dosage is 50 mg Promethazine HCl Oral Solution with an appropriately reduced dose of narcotic or barbiturate and the required amount of a belladonna alkaloid. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults. Promethazine HCL Oral Solution is contraindicated for children under 2 years of age.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:52:50 GMT 2023
by
admin
on
Sat Dec 16 05:52:50 GMT 2023
|
Record UNII |
75S19OE56R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
23724861
Created by
admin on Sat Dec 16 05:52:50 GMT 2023 , Edited by admin on Sat Dec 16 05:52:50 GMT 2023
|
PRIMARY | |||
|
SUB129213
Created by
admin on Sat Dec 16 05:52:50 GMT 2023 , Edited by admin on Sat Dec 16 05:52:50 GMT 2023
|
PRIMARY | |||
|
100000155242
Created by
admin on Sat Dec 16 05:52:50 GMT 2023 , Edited by admin on Sat Dec 16 05:52:50 GMT 2023
|
PRIMARY | |||
|
75S19OE56R
Created by
admin on Sat Dec 16 05:52:50 GMT 2023 , Edited by admin on Sat Dec 16 05:52:50 GMT 2023
|
PRIMARY | |||
|
69376-26-7
Created by
admin on Sat Dec 16 05:52:50 GMT 2023 , Edited by admin on Sat Dec 16 05:52:50 GMT 2023
|
NON-SPECIFIC SUBSTITUTION | |||
|
SUB04072MIG
Created by
admin on Sat Dec 16 05:52:50 GMT 2023 , Edited by admin on Sat Dec 16 05:52:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |